STOCK TITAN

Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

Ensysce Biosciences (NASDAQ:ENSC) announced its leadership team's participation in the 18th Annual Pain Therapeutics Summit on October 28-29, 2024, in Boston. Dr. Lynn Kirkpatrick, CEO, will present "When All You Have is a Hammer ... A New Approach to Soften the Blow" on October 28th at 1:00 PM ET. She will discuss Ensysce's TAAP™ and MPAR® opioid classes, including PF614 and PF614-MPAR, which aim to provide effective pain relief with reduced abuse potential and overdose protection.

Dr. William Schmidt, CMO, will serve as Chairperson for the second consecutive year, providing opening remarks on both days. The summit brings together leaders in advanced medicine, science, academia, and government to discuss the latest advances in novel pain therapies development.

Ensysce Biosciences (NASDAQ:ENSC) ha annunciato la partecipazione del suo team di leadership al 18° Summit Annuale sulle Terapie Antidolorifiche, che si terrà il 28-29 ottobre 2024 a Boston. Dr.ssa Lynn Kirkpatrick, CEO, presenterà "Quando hai solo un martello ... Un nuovo approccio per ammorbidire il colpo" il 28 ottobre alle 13:00 ET. Discuterà le classi di oppioidi TAAP™ e MPAR® di Ensysce, compresi PF614 e PF614-MPAR, che mirano a fornire un sollievo dal dolore efficace con un ridotto potenziale di abuso e protezione contro le overdose.

Dr. William Schmidt, CMO, ricoprirà il ruolo di Presidente per il secondo anno consecutivo, fornendo osservazioni iniziali in entrambi i giorni. Il summit riunisce leader nella medicina avanzata, nella scienza, nell'accademia e nel governo per discutere gli ultimi sviluppi nelle terapie innovative per il dolore.

Ensysce Biosciences (NASDAQ:ENSC) anunció la participación de su equipo de liderazgo en la 18ª Cumbre Anual de Terapias del Dolor, que se llevará a cabo el 28-29 de octubre de 2024 en Boston. Dr. Lynn Kirkpatrick, CEO, presentará "Cuando solo tienes un martillo ... Un nuevo enfoque para suavizar el golpe" el 28 de octubre a la 1:00 PM ET. Ella discutirá las clases de opioides TAAP™ y MPAR® de Ensysce, incluidos PF614 y PF614-MPAR, que buscan proporcionar un alivio del dolor efectivo con un menor potencial de abuso y protección contra sobredosis.

Dr. William Schmidt, CMO, será el presidente por segundo año consecutivo, ofreciendo comentarios de apertura en ambos días. La cumbre reúne a líderes en medicina avanzada, ciencia, academia y gobierno para discutir los últimos avances en el desarrollo de nuevas terapias para el dolor.

Ensysce Biosciences (NASDAQ:ENSC)는 2024년 10월 28-29일 보스턴에서 열리는 18회 연례 통증 치료 석학회의 리더십 팀 참여를 발표했습니다. Lynn Kirkpatrick 박사, CEO는 10월 28일 오후 1시(ET)에 "망치가 전부라면 ... 타격 완화를 위한 새로운 접근법"을 발표할 예정입니다. 그녀는 Ensysce의 TAAP™ 및 MPAR® 오피오이드 클래스, 즉 PF614 및 PF614-MPAR를 논의하며, 이는 약물 남용 가능성을 줄이고 과다복용을 방지하면서 효과적인 통증 완화를 제공하는 것을 목표로 하고 있습니다.

William Schmidt 박사, CMO는 두 번째 연속 연도 동안 의장을 맡아 양일 간 개회사를 할 예정입니다. 이번 회의는 최신 혁신적 통증 치료 개발 동향에 대해 논의하기 위해 선진 의학, 과학, 학계 및 정부의 리더들을 모으고 있습니다.

Ensysce Biosciences (NASDAQ:ENSC) a annoncé la participation de son équipe dirigeante au 18e Sommet Annuel sur les Thérapies de la Douleur, qui se tiendra les 28 et 29 octobre 2024 à Boston. Dr. Lynn Kirkpatrick, PDG, présentera "Quand tout ce que vous avez est un marteau ... Une nouvelle approche pour adoucir le coup" le 28 octobre à 13h00 ET. Elle discutera des classes d'opioïdes TAAP™ et MPAR® d'Ensysce, y compris PF614 et PF614-MPAR, qui visent à fournir un soulagement efficace de la douleur avec un potentiel d'abus réduit et une protection contre les surdoses.

Dr. William Schmidt, CMO, sera président pour la deuxième année consécutive, faisant des remarques d'ouverture les deux jours. Le sommet réunit des leaders en médecine avancée, en science, en milieu universitaire et au gouvernement pour discuter des dernières avancées dans le développement de nouvelles thérapies contre la douleur.

Ensysce Biosciences (NASDAQ:ENSC) kündigte die Teilnahme seines Führungsteams am 18. jährlichen Schmerztherapiegipfel am 28. und 29. Oktober 2024 in Boston an. Dr. Lynn Kirkpatrick, CEO, wird am 28. Oktober um 13:00 Uhr ET "Wenn alles, was du hast, ein Hammer ist ... Ein neuer Ansatz, um den Schlag abzumildern" präsentieren. Sie wird die Opioid-Klassen TAAP™ und MPAR® von Ensysce erörtern, einschließlich PF614 und PF614-MPAR, die darauf abzielen, eine wirksame Schmerzlinderung mit reduziertem Missbrauchspotential und Überdosierungsschutz bereitzustellen.

Dr. William Schmidt, CMO, wird zum zweiten Mal in Folge als Vorsitzender fungieren und an beiden Tagen die Eröffnungsrede halten. Der Gipfel vereint Führungspersönlichkeiten aus der fortschrittlichen Medizin, Wissenschaft, akademischen Kreisen und der Regierung, um die neuesten Entwicklungen in der Entwicklung neuartiger Schmerztherapien zu diskutieren.

Positive
  • Ensysce's leadership team participating in a prominent pain therapeutics summit
  • Presentation of clinical data for PF614 and PF614-MPAR, showcasing potential advantages over current Abuse Deterrent Formulation (ADF) opioids
  • TAAP and MPAR technologies aim to reduce multiple forms of abuse and provide oral overdose protection
Negative
  • None.

~ Dr. Lynn Kirkpatrick to Present Latest Clinical Data for PF614 and PF614-MPAR ~

~ Dr. William Schmidt to Deliver Opening Remarks as Summit Chair ~

SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, will present at the 18th Annual Pain Therapeutics Summit taking place on October 28 and 29, 2024 in Boston, MA.

Dr. Kirkpatrick's presentation "When All You Have is a Hammer ... A New Approach to Soften the Blow" will be held on Monday, October 28th at 1:00 PM Eastern Time.

In this session, Dr. Kirkpatrick will review the proliferation of new analgesic entrants that have promised opioid-like efficacy but to date have not delivered. The result has been opioid mistrust and unfortunately, a reduction in access for those who depend on opioid pain relief for a decent quality of life. Instead of turning away from these effective analgesics, Ensysce embraced their efficacy by introducing new TAAP™ and MPAR® classes of opioids. The lead agents, PF614 and PF614-MPAR, are expected to provide a novel option for high-risk patients delivering exquisite pain relief yet with advantages over currently used Abuse Deterrent Formulation (ADF) opioid products. TAAP-modified opioids reduce multiple forms of abuse and only release the opioid when taken orally and exposed to trypsin in the gut. MPAR applies another layer of safety resulting in oral overdose protection by adding a trypsin inhibitor to each of the TAAP products. Dr. Kirkpatrick will present clinical data demonstrating these unique qualities of TAAP and MPAR and supporting their added benefits over the ADF class.

Ensysce's commitment to the Annual Pain Therapeutics Summit is also represented by Dr. William Schmidt, Chief Medical Officer of Ensysce, who will serve as Chairperson for the second consecutive year. Dr. Schmidt will provide opening remarks on Monday, October 28th and Tuesday, October 29th. Dr. Schmidt has specialized in providing advice on preclinical and clinical studies of novel analgesic drugs throughout his career. Dr. Schmidt is the Parliamentarian and a Past President of the Eastern Pain Association. He received the John J. Bonica award for the development of new analgesics and his sustained contributions to the educational efforts of the Eastern Pain Association in 2014.

The Annual Pain Therapeutics Summit is a widely recognized arena for leaders in the fields of advanced medicine and science, academia and government to come together and discuss the latest advances in the quest to develop novel pain therapies. The summit will present thoughtful insight from key industry leaders and academic researchers concerning cutting edge drug discovery science, preclinical development trends, analysis of key clinical-stage pain therapies and newly marketed products. The agenda for this year's event includes a wide variety of topics in the field of pain research, such as the development of novel therapeutics, biomarkers associated with pain states, and clinical trial design considerations. Additionally, the event offers panel discussions on key issues facing pain research today from ethical considerations to funding challenges and beyond. The event is a prominent gathering of experts dedicated to improving the lives of those suffering from chronic pain. Please find more information here.

About Ensysce Biosciences

Ensysce Biosciences is a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.

Forward-Looking Statements

Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from its fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.

Ensysce Biosciences Company Contact:

Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196

Ensysce Biosciences Investor Relations Contact:

Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us

SOURCE: Ensysce Biosciences Inc.



View the original press release on accesswire.com

FAQ

What will Dr. Lynn Kirkpatrick present at the 18th Annual Pain Therapeutics Summit for Ensysce Biosciences (ENSC)?

Dr. Lynn Kirkpatrick will present 'When All You Have is a Hammer ... A New Approach to Soften the Blow' on October 28th at 1:00 PM ET, discussing Ensysce's TAAP™ and MPAR® opioid classes, including PF614 and PF614-MPAR.

What role will Dr. William Schmidt play at the 2024 Annual Pain Therapeutics Summit for Ensysce Biosciences (ENSC)?

Dr. William Schmidt, CMO of Ensysce Biosciences, will serve as Chairperson for the second consecutive year, providing opening remarks on both October 28th and 29th, 2024.

What are the key technologies Ensysce Biosciences (ENSC) is developing for pain relief?

Ensysce Biosciences is developing TAAP™ and MPAR® technologies, which aim to provide effective pain relief with reduced abuse potential and oral overdose protection. Their lead agents are PF614 and PF614-MPAR.

When and where will the 18th Annual Pain Therapeutics Summit featuring Ensysce Biosciences (ENSC) take place?

The 18th Annual Pain Therapeutics Summit will take place on October 28 and 29, 2024, in Boston, MA.

Ensysce Biosciences, Inc.

NASDAQ:ENSC

ENSC Rankings

ENSC Latest News

ENSC Stock Data

9.69M
14.91M
1.17%
3.35%
0.82%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LA JOLLA